Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
European Heart Journal
|
February 21, 2008
Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study
Sidney Chocron, Richard Baillot, Jean Lucien Rouleau, et al.
Circulation
|
December 12, 2007
Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery
Jean L Rouleau, Wayne J Warnica, Richard Baillot, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
June 4, 2011
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models
Konstantin H Dragnev, Tian Ma, Jobin Cyrus, et al.
Molecular Cancer Therapeutics
|
May 21, 2013
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer
Tian Ma, Fabrizio Galimberti, Cherie P Erkmen, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
European Heart Journal
|
February 21, 2008
Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study
Sidney Chocron, Richard Baillot, Jean Lucien Rouleau, et al.
Circulation
|
December 12, 2007
Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery
Jean L Rouleau, Wayne J Warnica, Richard Baillot, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
June 4, 2011
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models
Konstantin H Dragnev, Tian Ma, Jobin Cyrus, et al.
Molecular Cancer Therapeutics
|
May 21, 2013
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer
Tian Ma, Fabrizio Galimberti, Cherie P Erkmen, et al.
Page
of 5